Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status.

Jorge, Alexander A L; Edouard, Thomas; Maghnie, Mohamad; Pietropoli, Alberto; Kelepouris, Nicky; Romano, Alicia; Zenker, Martin; Horikawa, Reiko

Jorge, Alexander A L; Edouard, Thomas; Maghnie, Mohamad; Pietropoli, Alberto; Kelepouris, Nicky; Romano, Alicia; Zenker, Martin; Horikawa, Reiko.

Afiliação

Jorge AAL; Unidade de Endocrinologia-Genetica, LIM/25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.
Edouard T; Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, RESTORE INSERM UMR1301, Toulouse, France.
Maghnie M; Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Pietropoli A; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy.
Kelepouris N; Novo Nordisk Health Care AG, Global Medical Affairs Biopharm, Zürich, Switzerland.
Romano A; Novo Nordisk Inc., Clinical, Medical and Regulatory Biopharm-RED, Plainsboro, New Jersey, USA.
Zenker M; Department of Pediatrics, New York Medical College, Valhalla, New York, USA.
Horikawa R; Institute of Human Genetics & Department of Pediatrics, University Hospital, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Endocr Connect ; 11(4)2022 Apr 15.

Article em En | MEDLINE | ID: mdl-35245205

Palavras-chave

Noonan syndrome; PTPN11; RASopathies; growth hormone; short stature

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Endocr Connect Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google